These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28237195)

  • 1. Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs.
    Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
    Value Health; 2017 Feb; 20(2):200-205. PubMed ID: 28237195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
    Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
    Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
    J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verifying the value of existing frameworks for formulary review at a large academic health system: assessing inter-rater reliability.
    Karas BL; Picone MF; Werner S; Holsopple M
    J Manag Care Spec Pharm; 2021 Apr; 27(4):488-496. PubMed ID: 33769852
    [No Abstract]   [Full Text] [Related]  

  • 5. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
    Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
    Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology.
    Bae G; Bae S; Lee D; Han J; Koo DH; Kim DY; Kim HJ; Oh SY; Lee HY; Lee JH; Han HS; Ha H; Kang JH
    Int J Environ Res Public Health; 2021 Mar; 18(6):. PubMed ID: 33803663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
    Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
    Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
    Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
    J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups.
    Del Paggio JC; Cheng S; Booth CM; Cheung MC; Chan KKW
    JNCI Cancer Spectr; 2018 Jul; 2(3):pky050. PubMed ID: 31360865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating Oncology Value-Based Frameworks in the U.S. Marketplace and Challenges in Real-World Application: A Multiple Myeloma Test Case.
    Djatche LM; Goble JA; Chun G; Varga S
    J Manag Care Spec Pharm; 2018 Jan; 24(1):39-46. PubMed ID: 29290169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
    Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
    J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology.
    Shah-Manek B; Galanto JS; Nguyen H; Ignoffo R
    J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S13-S20. PubMed ID: 28535103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Choosing PD-1 Inhibitors in Oncology Setting, Left or Right?-Lessons From Value Assessment With ASCO-VF and ESMO-MCBS.
    Jiang Q; Feng M; Li Y; Lang J; Wei H; Yu T
    Front Pharmacol; 2020; 11():574511. PubMed ID: 33390946
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
    Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL
    J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials.
    Saluja R; Everest L; Cheng S; Cheung M; Chan KKW
    JAMA Oncol; 2019 Aug; 5(8):1188-1194. PubMed ID: 31095255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
    Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
    Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Comparison of Additional Benefit Assessment Methods for Time-to-Event Endpoints Using Hazard Ratio Point Estimates or Confidence Interval Limits by Means of a Simulation Study.
    Büsch CA; Kirchner M; Behnisch R; Kieser M
    Med Decis Making; 2024 May; 44(4):365-379. PubMed ID: 38721872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020.
    Luo J; Ou S; Wei H; Qin X; Peng R; Wang S; Jiang Q
    Front Public Health; 2023; 11():1109668. PubMed ID: 36908440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
    Everest L; Shah M; Chan KKW
    JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to Capturing Value in Oncology.
    Walter E
    Recent Results Cancer Res; 2019; 213():85-108. PubMed ID: 30543009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.